Suscripción a Biblioteca: Guest
Critical Reviews™ in Immunology

Publicado 6 números por año

ISSN Imprimir: 1040-8401

ISSN En Línea: 2162-6472

The Impact Factor measures the average number of citations received in a particular year by papers published in the journal during the two preceding years. 2017 Journal Citation Reports (Clarivate Analytics, 2018) IF: 1.3 To calculate the five year Impact Factor, citations are counted in 2017 to the previous five years and divided by the source items published in the previous five years. 2017 Journal Citation Reports (Clarivate Analytics, 2018) 5-Year IF: 2.6 The Eigenfactor score, developed by Jevin West and Carl Bergstrom at the University of Washington, is a rating of the total importance of a scientific journal. Journals are rated according to the number of incoming citations, with citations from highly ranked journals weighted to make a larger contribution to the eigenfactor than those from poorly ranked journals. Eigenfactor: 0.00079 The Journal Citation Indicator (JCI) is a single measurement of the field-normalized citation impact of journals in the Web of Science Core Collection across disciplines. The key words here are that the metric is normalized and cross-disciplinary. JCI: 0.24 SJR: 0.429 SNIP: 0.287 CiteScore™:: 2.7 H-Index: 81

Indexed in

Targeting OX40 and OX40L for the Treatment of Autoimmunity and Cancer

Volumen 27, Edición 5, 2007, pp. 415-436
DOI: 10.1615/CritRevImmunol.v27.i5.20
Get accessGet access

SINOPSIS

The optimal activation of naïve T cells requires TCR−mediated recognition of cognate peptide−MHC complexes on antigen presenting cells in the presence of costimulatory signals. Although signals provided via CD28−B7 interactions are important for enhancing the initial T−cell response, other costimulatory signals are required for sustaining the response and promoting both T−cell differentiation and survival. In particular, engagement of OX40 (CD134) by its natural ligand OX40L (CD134L) or OX40 agonists has been shown to provide key signals that can augment CD4 and CD8 T−cell responses. Importantly, numerous studies have highlighted the ability of OX40−specific agonists or antagonists to enhance antitumor immunity or ameliorate autoimmune disease, respectively. On the basis of these studies, the development of OX40− and OX40L−specific reagents has been pursued for clinical use. Given the emerging role of OX40 and OX40L as novel therapeutic targets, this review will focus on the cellular and molecular mechanisms of OX40−mediated T−cell costimulation with a special emphasis on the role of OX40-OX40L interactions in the etiology and treatment of autoimmunity and cancer.

CITADO POR
  1. Lee Chern Siang, Cragg Mark, Glennie Martin, Johnson Peter, Novel antibodies targeting immune regulatory checkpoints for cancer therapy, British Journal of Clinical Pharmacology, 76, 2, 2013. Crossref

  2. Wang Qin, Chen Yongjing, Xie Fang, Ge Yan, Wang Xuefeng, Zhang Xueguang, A Novel Agonist Anti-Human OX40L Monoclonal Antibody That Stimulates T Cell Proliferation and Enhances Cytokine Secretion, Hybridoma, 28, 4, 2009. Crossref

  3. Tomei Sara, Wang Ena, Delogu Lucia Gemma, Marincola Francesco M, Bedognetti Davide, Non-BRAF-targeted therapy, immunotherapy, and combination therapy for melanoma, Expert Opinion on Biological Therapy, 14, 5, 2014. Crossref

  4. Murphy Judith T., Burey Andre P., Beebe Amy M., Gu Danling, Presta Leonard G., Merghoub Taha, Wolchok Jedd D., Anaphylaxis caused by repetitive doses of a GITR agonist monoclonal antibody in mice, Blood, 123, 14, 2014. Crossref

  5. Hirschhorn-Cymerman Daniel, Rizzuto Gabrielle A., Merghoub Taha, Cohen Adam D., Avogadri Francesca, Lesokhin Alexander M., Weinberg Andrew D., Wolchok Jedd D., Houghton Alan N., OX40 engagement and chemotherapy combination provides potent antitumor immunity with concomitant regulatory T cell apoptosis, Journal of Experimental Medicine, 206, 5, 2009. Crossref

  6. Schrama D., Hauschild A., Becker J.C., Immunmodulierende Antikörper in der Dermatoonkologie, Der Hautarzt, 59, 10, 2008. Crossref

  7. Chen Mingshui, Ouyang Haichao, Zhou Shangyong, Li Jieyu, Ye Yunbin, PLGA-nanoparticle mediated delivery of anti-OX40 monoclonal antibody enhances anti-tumor cytotoxic T cell responses, Cellular Immunology, 287, 2, 2014. Crossref

  8. Redmond William L., Gough Michael J., Weinberg Andrew D., Ligation of the OX40 co-stimulatory receptor reverses self-Ag and tumor-induced CD8 T-cell anergy in vivo , European Journal of Immunology, 39, 8, 2009. Crossref

  9. Chu Haiyan, Hui Gaoyun, Yuan Lin, Shi Danni, Wang Yubang, Du Mulong, Zhong Dongyan, Ma Lan, Tong Na, Qin Chao, Yin Changjun, Zhang Zhengdong, Wang Meilin, Identification of novel piRNAs in bladder cancer, Cancer Letters, 356, 2, 2015. Crossref

  10. Buglio Daniela, Mamidipudi Vidya, Khaskhely Noor M., Brady Helen, Heise Carla, Besterman Jeffrey, Martell Robert E., MacBeth Kyle, Younes Anas, The class-I HDAC inhibitor MGCD0103 induces apoptosis in Hodgkin lymphoma cell lines and synergizes with proteasome inhibitors by an HDAC6-independent mechanism, British Journal of Haematology, 151, 4, 2010. Crossref

  11. Cuesta Ángel M., Sainz-Pastor Noelia, Bonet Jaume, Oliva Baldomero, Álvarez-Vallina Luis, Multivalent antibodies: when design surpasses evolution, Trends in Biotechnology, 28, 7, 2010. Crossref

  12. Sanmamed Miguel F., Pastor Fernando, Rodriguez Alfonso, Perez-Gracia Jose Luis, Rodriguez-Ruiz Maria E., Jure-Kunkel Maria, Melero Ignacio, Agonists of Co-stimulation in Cancer Immunotherapy Directed Against CD137, OX40, GITR, CD27, CD28, and ICOS, Seminars in Oncology, 42, 4, 2015. Crossref

  13. Linch Stefanie N., McNamara Michael J., Redmond William L., OX40 Agonists and Combination Immunotherapy: Putting the Pedal to the Metal, Frontiers in Oncology, 5, 2015. Crossref

  14. Bell R. Bryan, Leidner Rom S., Crittenden Marka R., Curti Brendan D., Feng Zipei, Montler Ryan, Gough Michael J., Fox Bernard A., Weinberg Andrew D., Urba Walter J., OX40 signaling in head and neck squamous cell carcinoma: Overcoming immunosuppression in the tumor microenvironment, Oral Oncology, 52, 2016. Crossref

  15. Weinberg Andrew D., Morris Nicholas P., Kovacsovics-Bankowski Magdalena, Urba Walter J., Curti Brendan D., Science gone translational: the OX40 agonist story, Immunological Reviews, 244, 1, 2011. Crossref

  16. Buglio Daniela, Khaskhely Noor M., Voo Kui Shin, Martinez-Valdez Hector, Liu Yong-Jun, Younes Anas, HDAC11 plays an essential role in regulating OX40 ligand expression in Hodgkin lymphoma, Blood, 117, 10, 2011. Crossref

  17. Park Jong Chul, Hahn Noah M., Emerging role of immunotherapy in urothelial carcinoma—Future directions and novel therapies, Urologic Oncology: Seminars and Original Investigations, 34, 12, 2016. Crossref

  18. Redmond William L., Linch Stefanie N., Combinatorial immunotherapeutic approaches to restore the function of anergic tumor-reactive cytotoxic CD8+ T cells, Human Vaccines & Immunotherapeutics, 12, 10, 2016. Crossref

  19. Montler Ryan, Bell R Bryan, Thalhofer Colin, Leidner Rom, Feng Zipei, Fox Bernard A, Cheng Allen C, Bui Tuan G, Tucker Christopher, Hoen Helena, Weinberg Andrew, OX40, PD-1 and CTLA-4 are selectively expressed on tumor-infiltrating T cells in head and neck cancer, Clinical & Translational Immunology, 5, 4, 2016. Crossref

  20. Maherzi C., Onodi F., Tartour E., Terme M., Tanchot C., Strategies to Reduce Intratumoral Regulatory T Cells, in Oncoimmunology, 2018. Crossref

  21. Domingos Patrícia Luciana Batista, Viana Agostinho Gonçalves, Fraga Carlos Alberto de Carvalho, Bonan Paulo Rogério Ferreti, OX40+ T lymphocytes and IFN-γ are associated with American tegumentary leishmaniasis pathogenesis, Anais Brasileiros de Dermatologia, 87, 6, 2012. Crossref

  22. Melero Ignacio, Pérez-Ruiz Elisabeth, Sanchez-Paulete Alfonso R., Teijeira Alvaro, Aznar Angela, Sanmamed Miguel F., Co-stimulation Agonists via CD137, OX40, GITR, and CD27 for Immunotherapy of Cancer, in Oncoimmunology, 2018. Crossref

  23. Solinas Cinzia, Gombos Andrea, Latifyan Sofiya, Piccart-Gebhart Martine, Kok Marleen, Buisseret Laurence, Targeting immune checkpoints in breast cancer: an update of early results, ESMO Open, 2, 5, 2017. Crossref

  24. Pham Minh Ngoc, Murata Satoshi, Kitamura Naomi, Ueki Tomoyuki, Kojima Masatsugu, Miyake Toru, Takebayashi Katsushi, Kodama Hirokazu, Mekata Eiji, Tani Masaji, In vivoantitumor function of tumor antigen-specific CTLs generated in the presence of OX40 co-stimulationin vitro, International Journal of Cancer, 142, 11, 2018. Crossref

  25. Weinberg Andrew D., The Role of OX40 (CD134) in T-Cell Memory Generation, in Memory T Cells, 684, 2010. Crossref

  26. Qui Harry Z., Hagymasi Adam T., Bandyopadhyay Suman, St. Rose Marie-Clare, Ramanarasimhaiah Raghunath, Ménoret Antoine, Mittler Robert S., Gordon Scott M., Reiner Steven L., Vella Anthony T., Adler Adam J., CD134 Plus CD137 Dual Costimulation Induces Eomesodermin in CD4 T Cells To Program Cytotoxic Th1 Differentiation, The Journal of Immunology, 187, 7, 2011. Crossref

  27. Wing James Badger, Tay Christopher, Sakaguchi Shimon, Control of Regulatory T Cells by Co-signal Molecules, in Co-signal Molecules in T Cell Activation, 1189, 2019. Crossref

  28. Vieyra-Garcia Pablo, Crouch Jack D., O’Malley John T., Seger Edward W., Yang Chao H., Teague Jessica E., Vromans Anna Maria, Gehad Ahmed, Win Thet Su, Yu Zizi, Lowry Elizabeth L., Na Jung-Im, Rook Alain H., Wolf Peter, Clark Rachael A., Benign T cells drive clinical skin inflammation in cutaneous T cell lymphoma, JCI Insight, 4, 1, 2019. Crossref

  29. Malamas Anthony S., Hammond Scott A., Schlom Jeffrey, Hodge James W., Combination therapy with an OX40L fusion protein and a vaccine targeting the transcription factor twist inhibits metastasis in a murine model of breast cancer, Oncotarget, 8, 53, 2017. Crossref

  30. Lei Wei , Zeng Daxiong , Liu Gaoqin , Zhu Yehan , Wang Jiajia , Wu Hongya , Jiang Junhong , Huang Jianan , Crucial role of OX40/OX40L signaling in a murine model of asthma, Molecular Medicine Reports, 2018. Crossref

  31. Amon Lukas, Hatscher Lukas, Heger Lukas, Dudziak Diana, Lehmann Christian H. K., Harnessing the Complete Repertoire of Conventional Dendritic Cell Functions for Cancer Immunotherapy, Pharmaceutics, 12, 7, 2020. Crossref

  32. Stachyra Karolina, Dudzisz-Śledź Monika, Bylina Elżbieta, Szumera-Ciećkiewicz Anna, Spałek Mateusz J., Bartnik Ewa, Rutkowski Piotr, Czarnecka Anna M., Merkel Cell Carcinoma from Molecular Pathology to Novel Therapies, International Journal of Molecular Sciences, 22, 12, 2021. Crossref

  33. Darwish Martine, Shatz Whitney, Leonard Brandon, Loyet Kelly, Barrett Kathy, Wong Janice L., Li Hong, Abraham Ryan, Lin May, Franke Yvonne, Tam Christine, Mortara Kyle, Zilberleyb Inna, Blanchette Craig, Nanolipoprotein Particles as a Delivery Platform for Fab Based Therapeutics, Bioconjugate Chemistry, 31, 8, 2020. Crossref

  34. Kondo Kayo, Okuma Kazu, Tanaka Reiko, Matsuzaki Goro, Ansari Aftab A., Tanaka Yuetsu, Rapid induction of OX40 ligand on primary T cells activated under DNA-damaging conditions, Human Immunology, 69, 9, 2008. Crossref

  35. Leyland Rebecca, Watkins Amanda, Mulgrew Kathy A., Holoweckyj Nicholas, Bamber Lisa, Tigue Natalie J., Offer Emily, Andrews John, Yan Li, Mullins Stefanie, Oberst Michael D., Coates Ulrichsen Jane, Leinster David A., McGlinchey Kelly, Young Lesley, Morrow Michelle, Hammond Scott A., Mallinder Philip, Herath Athula, Leow Ching Ching, Wilkinson Robert W., Stewart Ross, A Novel Murine GITR Ligand Fusion Protein Induces Antitumor Activity as a Monotherapy That Is Further Enhanced in Combination with an OX40 Agonist, Clinical Cancer Research, 23, 13, 2017. Crossref

  36. Sturgill Elizabeth R., Rolig Annah S., Linch Stefanie N., Mick Courtney, Kasiewicz Melissa J., Sun Zhaoyu, Traber Peter G., Shlevin Harold, Redmond William L., Galectin-3 inhibition with belapectin combined with anti-OX40 therapy reprograms the tumor microenvironment to favor anti-tumor immunity, OncoImmunology, 10, 1, 2021. Crossref

  37. Curti Brendan D., Kovacsovics-Bankowski Magdalena, Morris Nicholas, Walker Edwin, Chisholm Lana, Floyd Kevin, Walker Joshua, Gonzalez Iliana, Meeuwsen Tanisha, Fox Bernard A., Moudgil Tarsem, Miller William, Haley Daniel, Coffey Todd, Fisher Brenda, Delanty-Miller Laurie, Rymarchyk Nicole, Kelly Tracy, Crocenzi Todd, Bernstein Eric, Sanborn Rachel, Urba Walter J., Weinberg Andrew D., OX40 Is a Potent Immune-Stimulating Target in Late-Stage Cancer Patients, Cancer Research, 73, 24, 2013. Crossref

Próximos Artículos

Identification of a novel five-gene prognostic model for laryngeal cancer associated with mitophagy using integrated bioinformatics analysis and experimental verification Dong Song, Lun Dong, Mei Wang, Xiaoping Gao Function of steroid receptor coactivators (SRCs) in T cells and cancers: Implications for cancer immunotherapy Wencan Zhang, Xu Cao, Hongmin Wu, Xiancai Zhong, Yun Shi, Zuoming Sun Electroacupuncture Alleviates Ischemic Stroke by Activating the mTOR/SREBP1 Pathway Jiawang Lang, Jianchang Luo, Luodan Wang, Wenbin Xu, Jie Jia, Zhipeng Zhao, Boxu Lang KIAA1429 induces the m6A modification of LINC01106 to enhance the malignancy of lung adenocarcinoma cell via JAK/STAT3 pathway Di Xu, Ziming Wang, Fajiu Li Effect of p-estrogen receptor at serine on its function and breast growth Yuan Liang, Junhui Qin, Tiancheng Ma, Tong Yang, Zhenyu Ke, Ruian Wang Mechanistic Insights into Tanshinone IIA in the Amelioration of Post-Thyroidectomy Hypoparathyroidism Xiaoyu Qian, Lin Li, Liang Chen, Chao Shen, Jian Tang MiRNA let-7d-5p alleviates inflammatory responses by targeting Map3k1 and inactivating ERK/p38 MAPK signaling in microglia Fan Fang, Cheng Chen Role of Natural Killer Cells as Cell-Based Immunotherapy in Oral Tumor Eradication and Differentiation Both In Vivo and In Vitro Kawaljit Kaur, Anahid Jewett The Current and Future States of Natural Killer Cell-Based Immunotherapy in Hepatocellular Carcinoma Tu Nguyen, Po-Chun Chen, Janet Pham, Kawaljit Kaur, Steven Raman, Anahid Jewett, Jason Chiang Phillygenin alleviated arthritis through the inhibition of NLRP3 inflammasome and Ferroptosis by AMPK Jianghui Wang, Shufang Ni, Kai Zheng, Yan Zhao, peihong zhang, Hong Chang The value of systemic immune-inflammation index and T cell subsets in the severity and prognosis of sepsis Hao Zhou Efficacy and Nuances of Precision Molecular Engineering for Hodgkin's Disease to a Gene Therapeutic Approach Muhammad Imran Qadir, Bilal Ahmed, Nadir Hussain Serum interleukin 6 and ferritin levels are the independent risk factors for pneumonia in elderly patients Hao Yuan, Jing Tian, Lu Wen Exploration of diagnostic markers associated with inflammation in chronic kidney disease (CKD) based on WGCNA and machine learning Qianjia Wu, Yang Yang, Chongze Lin Clinical significance of serum CTRP3 level in the prediction of cardiac dysfunction and intestinal mucosal barrier dysfunction in patients with severe acute pancreatitis Qiang Shao, Lin Sun The protective effect and mechanism of mild hypothermia on pig lung injury after cardiopulmonary resuscitation Jinlin Ren, Fangfang Zhu, Dongdong Sang, Mulin Cong, Shujuan Jiang Exploring mechanism of Zilongjin in treating lung adenocarcinoma based on network pharmacology combined with experimental verification Kang Zhang, Xiaoqun Chen Gastric Cancer Immune Subtypes and Prognostic Modeling: Insights from Aging-Related Genes Analysis Jian Shen, Minzhe Li Effects of different doses of dexmedetomidine on the prevention of postoperative sleep disturbance and serum neurotransmitter level in patients under general anesthesia Huifei Lu, Fei He, Ying Huang, Zhongliang Wei Identification of key ubiquitination-related genes and their associated with immune infiltration in osteoarthritis based on mRNA-miRNA network Dalu Yuan, Hailiang Shen, Lina Bai, Menglin Li, Qiujie Ye Diagnostic and Prognostic value of peripheral neutrophil CD64 index in elderly patients with community-acquired pneumonia Yan Li, Jing Zhang, Suhang Wang, Jie Cao Identification of Metabolism-Related Prognostic Biomarkers and Immune Features of Head and Neck Squamous Cell Carcinoma Rongjin Zhou, Junguo Wang Downregulation of miR-503-5p promotes the development of pancreatic cancer via targeting cyclin E2 Fei Li, Ying-pei Ling, Pan Wang, Shi-cheng Gu, Hao Jiang, Jie Zhu
Portal Digitalde Biblioteca Digital eLibros Revistas Referencias y Libros de Ponencias Colecciones Precios y Políticas de Suscripcione Begell House Contáctenos Language English 中文 Русский Português German French Spain